drugset / Trial / NCT07654751

A Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically

NCT07654751

Phase 4 Not yet recruiting 10 enrolled Janssen Research & Development, LLC
Non-randomizedParallel-groupOpen-labelOther

Summary

The purpose of this post-marketing study is to assess the amount of guselkumab in breast milk of lactating women receiving guselkumab as part of their standard clinical care provided by their treating physician, for any of the approved indications.

Timeline

Start
2026-06-15
Primary completion
2027-08-31
Completion
2027-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Guselkumab Monoclonal antibody 100 mg
Subject Guselkumab Monoclonal antibody 200 mg